An abnormal curve is not yet a proved inhibition mechanism
Both answers recognise inherited prothrombin dysfunction. MontMedical more precisely separates the transferred preparation, the peptide signal and proof of antithrombin resistance.
A selected synthetic development case, published by MontMedical. The clinical fingerprints match, but the exact prompts submitted to OpenEvidence were not independently retained. This is an editorial comparison of historical answers, not a blinded efficacy trial.
Our editorial assessment
How the retained answers rate.
OpenEvidence7.4/10
MontMedical8.7/10
MontMedical is stronger on experimental interpretation.
Same five criteria and weights for both systems
Criterion and weight
OpenEvidence
MontMedical
Diagnosis and case fit 25%
9/10
9/10
Interpretation of tests and experiments 25%
6/10
9/10
Strength of the claims 20%
6/10
9/10
Decisions and next steps 15%
8/10
8/10
Clarity and teaching 15%
8/10
8/10
Why each criterion received its mark
Diagnosis and case fit
OpenEvidence · 9/10: Recognises the familial qualitative factor-II pattern and a coherent resistance mechanism.
MontMedical · 9/10: Integrates the family phenotype and activity–antigen discordance into the leading diagnosis.
Interpretation of tests and experiments
OpenEvidence · 6/10: Assigns the swap to the molecule itself and gives the peptide tail more mechanistic specificity than the controls establish.
MontMedical · 9/10: Separates preparation-level transfer, complex-immunoassay signal and peptide cleavage from clotting-active enzyme decay.
Strength of the claims
OpenEvidence · 6/10: The leading hypothesis is justified; exact variant-level causation and inhibition kinetics are stated too firmly.
MontMedical · 9/10: Maintains the strong diagnosis while leaving the specific inhibition mechanism to the missing experiment.
Decisions and next steps
OpenEvidence · 8/10: Sequencing, segregation and family assessment are useful, but direct separated inhibition testing is less explicit.
MontMedical · 8/10: Names sequence-defined reconstitution and activation-separated decay as discriminating tests; less complete on longer-term care.
Clarity and teaching
OpenEvidence · 8/10: Clear and practical, although the long opening bundles diagnosis, molecular cause and assay interpretation.
MontMedical · 8/10: Structured and focused; some assay terminology still needs a simpler physiological explanation.
AI-assisted editorial judgment of these historical texts, published by MontMedical. Read the rubric, anchors and limits. These are answer-quality scores, not measured diagnostic accuracy or patient benefit.
The actual retained wording
OpenEvidence vs MontMedical.
These are verbatim passages from the retained answers, not rewritten examples. Bold, link formatting and line breaks have been removed. Each labelled passage is contiguous; an excerpt may begin within a sentence. Our interpretation and scores are separate.
OpenEvidence
Retained 2026-09-25
Localisation claim
The depletion/reconstitution data (abnormal curve transfers with patient-derived factor II, normalizes when patient factor II is replaced by control factor II) localizes the defect to the prothrombin molecule itself rather than to antithrombin, other inhibitors, or a lupus-type interference, consistent with prior functional characterization of these sodium-binding-loop mutants.
Late substrate signal
the classic signature of thrombin that escapes antithrombin inactivation but remains partially controlled by alpha-2-macroglobulin, which still permits small chromogenic/fluorogenic substrate cleavage after AT-mediated quenching would normally silence the signal.
MontMedical
Retained 2026-09-25
Localisation claim
The controlled swap localises the lower-peak, prolonged-tail assay phenotype to the patient-derived factor II preparation, with processing controls reducing a simple swap artefact. It does not identify which molecule in that preparation is responsible; comparison of a sequence-matched candidate variant with control prothrombin in a fresh reconstituted system could distinguish a variant-specific effect from activity carried by another component.
Complex-immunoassay interpretation
The lower complex immunoassay signal is compatible with impaired thrombin–antithrombin complex formation, but could also reflect a difference in how much thrombin was generated.
The case and the decision
A man has recurrent unprovoked venous thrombosis, relatives with low factor II clotting activity but normal antigen, and a prolonged thrombin-generation tail. Reciprocal replacement experiments make that curve follow the patient-derived factor II preparation. No coding variant has been identified, and the preparation contains unseparated molecular species.
Where MontMedical gives the stronger account
OpenEvidence favours antithrombin-resistant dysprothrombinemia, a coherent leading mechanism. It then assigns the transfer to the prothrombin molecule itself and treats the long tail as the characteristic inhibition defect. MontMedical keeps the strong familial diagnosis while identifying what the experiment actually transfers: the patient-derived preparation.
A preparation-level result is valuable localisation. A sequence-defined protein comparison would determine whether a particular variant reproduces it. That is a more precise next step than treating molecular causation as already demonstrated.
Why the distinction matters
Small peptides can be cleaved by alpha-2-macroglobulin-bound thrombin even when its action on large clotting substrates is restricted. A second small peptide corroborates cleavage; it does not independently establish late fibrinogen clotting. Published assay work supports that distinction. [1]
Likewise, lower complex-immunoassay signal can reflect less enzyme generated, altered recognition or impaired complex formation. Matched starting active enzyme, separated activation and inhibition, and an independent complex readout would test the inhibition claim directly.
What OpenEvidence gets right
It identifies an important, published mechanism and explains why a negative G20210A test does not cover coding variants. Its sequencing and family-assessment discussion is practical. The original Yukuhashi study did demonstrate resistance using a characterised variant; that provides precedent, rather than confirmation of the teaching case's unsequenced protein. [2]
Our preference here concerns the experiment-to-mechanism inference, not a claim that OpenEvidence missed the leading disorder.
Retained answer dates: MontMedical 2026-09-25; OpenEvidence 2026-09-25. Excerpt wording was checked against the retained answers; formatting was removed. These versions were selected during development. Complete original run settings and identical submitted prompts are not documented.
This article examines the MontMedical Pro beta using retained diagnostic answers.